• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1.5 Contact Hour(s)

    Release Date

    Thursday, October 31, 2019

    Offline Date

    Thursday, April 30, 2020

    ACPE Expiration Date

    Monday, October 31, 2022

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      Treatments for acute myeloid leukemia (AML) had remained essentially unchanged for several years; however, the advent of molecular testing has generated insight into the biology of this disease which is now being translated into clinical practice.  Several new therapies have emerged that have changed the current landscape of AML.  The introduction of CPX-351 offers a novel strategy for treating patients with therapy-related AML or AML with myelodysplasia-related changes; gemtuzumab ozogamicin may become incorporated into standard induction therapy, especially for patients with core-binding factor leukemias; and for older adults, combination therapy with venetoclax may offer a more efficacious strategy than the single-agent regimens previously used. Additionally, targeted therapies are now becoming available for patients with mutations in FMS-like tyrosine kinase 3 (FLT3) or isocitrate dehydrogenase 1 or 2, ushering in an era of personalized medicine in the treatment of AML.  All of these new therapies require novel implementation and evaluation for patients. 
       

      Handouts

      • Slide Document :   ce_8_slides.pdf

      Financial Support By

      joint funding from Advanced Accelerator Applications, a Novartis Company, Agios, BMS and Pfizer Alliance, Celgene Corporation, Merck & Co., Inc, and Pfizer
    • Pharmacist

      Describe novel and emerging therapeutic options in AML and their mechanisms of action (MOAs)
      Describe the currently available treatment strategies for patients with Acute Myeloid Leukemia (AML)
      Recognize safety and efficacy data for novel and emerging therapeutic options

      Nurse

      Recognize safety and efficacy data for novel and emerging therapeutic options
      Describe novel and emerging therapeutic options in AML and their mechanisms of action (MOAs)
      Describe the currently available treatment strategies for patients with Acute Myeloid Leukemia (AML)
    • Activity Type

      Knowledge

      CE Broker

      20-747618

      Universal Activity Number

      Pharmacist 0798-0000-19-191-H01-P
      Nurse 0798-0000-19-191-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      Ali  McBride, PharmD, MS, BCOP, FAzPA, FASHP
      Clinical Coordinator of Hematology/Oncology ,The University of Arizona Cancer Center; Clinical Assistant Professor, The University of Arizona College of Pharmacy

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).